keyword
https://read.qxmd.com/read/37941026/personalising-genetic-counselling-poetic-trial-protocol-for-a-hybrid-type-ii-effectiveness-implementation-randomised-clinical-trial-of-a-patient-screening-tool-to-improve-patient-empowerment-after-cancer-genetic-counselling
#1
JOURNAL ARTICLE
Laura E Forrest, Erin Tutty, Anurika P De Silva, Lara Petelin, Amy Ruscigno, Rebecca Purvis, Katrina Monohan, Maira Kentwell, Adrienne Sexton, Lesley Stafford, Paul A James
BACKGROUND: Genetic counselling aims to identify, and address, patient needs while facilitating informed decision-making about genetic testing and promoting empowerment and adaptation to genetic information. Increasing demand for cancer genetic testing and genetic counsellor workforce capacity limitations may impact the quality of genetic counselling provided. The use of a validated genetic-specific screening tool, the Genetic Psychosocial Risk Instrument (GPRI), may facilitate patient-centred genetic counselling...
November 8, 2023: Trials
https://read.qxmd.com/read/37419892/molecular-profiling-of-aromatase-inhibitor-sensitive-and-resistant-er-her2-postmenopausal-breast-cancers
#2
JOURNAL ARTICLE
Eugene F Schuster, Elena Lopez-Knowles, Anastasia Alataki, Lila Zabaglo, Elizabeth Folkerd, David Evans, Kally Sidhu, Maggie Chon U Cheang, Holly Tovey, Manuel Salto-Tellez, Perry Maxwell, John Robertson, Ian Smith, Judith M Bliss, Mitch Dowsett
Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with oestrogen receptor positive (ER+) breast cancer (BC), but >20% of patients will eventually relapse. Given the limited understanding of intrinsic resistance in these tumours, here we conduct a large-scale molecular analysis to identify features that impact on the response of ER + HER2- BC to AI. We compare the 15% of poorest responders (PRs, n = 177) as measured by proportional Ki67 changes after 2 weeks of neoadjuvant AI to good responders (GRs, n = 190) selected from the top 50% responders in the POETIC trial and matched for baseline Ki67 categories...
July 7, 2023: Nature Communications
https://read.qxmd.com/read/37046348/clinico-pathologic-relationships-with-ki67-and-its-change-with-short-term-aromatase-inhibitor-treatment-in-primary-er%C3%A2-%C3%A2-breast-cancer-further-results-from-the-poetic-trial-cruk-07-015
#3
RANDOMIZED CONTROLLED TRIAL
Judith M Bliss, Holly Tovey, Abigail Evans, Chris Holcombe, Kieran Horgan, Elizabeth Mallon, Raghavan Vidya, Anthony Skene, Andrew Dodson, Margaret Hills, Simone Detre, Lila Zabaglo, Jane Banerji, Lucy Kilburn, James P Morden, John F R Robertson, Ian Smith, Mitch Dowsett
PURPOSE: Ki67 assessed at diagnosis (Ki67baseline ) is an important prognostic factor in primary oestrogen receptor-positive (ER +) breast cancer. Proportional change in Ki67 after 2 weeks (∆Ki672week ) is associated with clinical benefit from endocrine therapies and residual Ki67 (Ki672week ) with recurrence-free survival. The aim was to define the association between Ki67baseline and after aromatase inhibitor (AI) exposure ∆Ki672week and Ki672week with key prognostic and biologic factors utilising data from the POETIC study...
April 12, 2023: Breast Cancer Research: BCR
https://read.qxmd.com/read/35985932/her2-enriched-subtype-and-novel-molecular-subgroups-drive-aromatase-inhibitor-resistance-and-an-increased-risk-of-relapse-in-early-er-her2-breast-cancer
#4
JOURNAL ARTICLE
Milana A Bergamino, Elena López-Knowles, Gabriele Morani, Holly Tovey, Lucy Kilburn, Eugene F Schuster, Anastasia Alataki, Margaret Hills, Hui Xiao, Chris Holcombe, Anthony Skene, John F Robertson, Ian E Smith, Judith M Bliss, Mitch Dowsett, Maggie C U Cheang
BACKGROUND: Oestrogen receptor positive/ human epidermal growth factor receptor positive (ER+/HER2+) breast cancers (BCs) are less responsive to endocrine therapy than ER+/HER2- tumours. Mechanisms underpinning the differential behaviour of ER+HER2+ tumours are poorly characterised. Our aim was to identify biomarkers of response to 2 weeks' presurgical AI treatment in ER+/HER2+ BCs. METHODS: All available ER+/HER2+ BC baseline tumours (n=342) in the POETIC trial were gene expression profiled using BC360™ (NanoString) covering intrinsic subtypes and 46 key biological signatures...
August 11, 2022: EBioMedicine
https://read.qxmd.com/read/34965950/impact-of-duration-of-neoadjuvant-aromatase-inhibitors-on-molecular-expression-profiles-in-estrogen-receptor-positive-breast-cancers
#5
JOURNAL ARTICLE
Milana A Bergamino, Gabriele Morani, Joel Parker, Eugene F Schuster, Mariana F Leal, Elena López-Knowles, Holly Tovey, Judith M Bliss, John F R Robertson, Ian E Smith, Mitch Dowsett, Maggie C U Cheang
PURPOSE: Aromatase inhibitor (AI) treatment is the standard of care for postmenopausal women with primary estrogen receptor-positive breast cancer. The impact of duration of neoadjuvant endocrine therapy (NET) on molecular characteristics is still unknown. We evaluated and compared changes of gene expression profiles under short-term (2-week) versus longer-term neoadjuvant AIs. EXPERIMENTAL DESIGN: Global gene expression profiles from the PeriOperative Endocrine Therapy for Individualised Care (POETIC) trial (137 received 2 weeks of AIs and 47 received no treatment) and targeted gene expression from 80 patients with breast cancer treated with NET for more than 1 month (NeoAI) were assessed...
December 29, 2021: Clinical Cancer Research
https://read.qxmd.com/read/33152284/long-term-outcome-and-prognostic-value-of-ki67-after-perioperative-endocrine-therapy-in-postmenopausal-women-with-hormone-sensitive-early-breast-cancer-poetic-an-open-label-multicentre-parallel-group-randomised-phase-3-trial
#6
RANDOMIZED CONTROLLED TRIAL
Ian Smith, John Robertson, Lucy Kilburn, Maggie Wilcox, Abigail Evans, Chris Holcombe, Kieran Horgan, Cliona Kirwan, Elizabeth Mallon, Mark Sibbering, Anthony Skene, Raghavan Vidya, Maggie Cheang, Jane Banerji, James Morden, Kally Sidhu, Andrew Dodson, Judith M Bliss, Mitch Dowsett
BACKGROUND: Preoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It has also been suggested that tumour Ki67 values after 2 weeks (Ki672W ) of POAI predicts individual patient outcome better than baseline Ki67 (Ki67B ). The POETIC trial aimed to test these two hypotheses. METHODS: POETIC was an open-label, multicentre, parallel-group, randomised, phase 3 trial (done in 130 UK hospitals) in which postmenopausal women aged at least 50 years with WHO performance status 0-1 and hormone receptor-positive, operable breast cancer were randomly assigned (2:1) to POAI (letrozole 2·5 mg per day orally or anastrozole 1 mg per day orally) for 14 days before and following surgery or no POAI (control)...
November 2020: Lancet Oncology
https://read.qxmd.com/read/31892336/impact-of-aromatase-inhibitor-treatment-on-global-gene-expression-and-its-association-with-antiproliferative-response-in-er-breast-cancer-in-postmenopausal-patients
#7
JOURNAL ARTICLE
Qiong Gao, Elena López-Knowles, Maggie Chon U Cheang, James Morden, Ricardo Ribas, Kally Sidhu, David Evans, Vera Martins, Andrew Dodson, Anthony Skene, Chris Holcombe, Elizabeth Mallon, Abigail Evans, Judith M Bliss, John Robertson, Ian Smith, Lesley-Ann Martin, Mitch Dowsett
BACKGROUND: Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major clinical problem. In this study, we sought to investigate the impact of aromatase inhibitor (AI) therapy on gene expression and identify gene modules representing key biological pathways that relate to early AI therapy resistance. METHODS: Global gene expression was measured on pairs of core-cut biopsies taken at baseline and at surgery from 254 patients with ER-positive primary breast cancer randomised to receive 2-week presurgical AI (n = 198) or no presurgical treatment (control n = 56) from the POETIC trial...
December 31, 2019: Breast Cancer Research: BCR
https://read.qxmd.com/read/31182656/poetic-program-for-enhanced-training-in-cancer-an-initial-experience-of-supporting-capacity-building-for-oncology-training-in-sub-saharan-africa
#8
JOURNAL ARTICLE
Madeleine Fish, Jeannette Parkes, Nazima Dharsee, Scott Dryden-Peterson, Jason Efstathiou, Lowell Schnipper, Bruce A Chabner, Aparna R Parikh
BACKGROUND: Sub-Saharan Africa is simultaneously facing a rising incidence of cancer and a dearth of medical professionals because of insufficient training numbers and emigration, creating a growing shortage of cancer care. To combat this, Massachusetts General Hospital and Beth Israel Deaconess Medical Center partnered with institutions in South Africa, Tanzania, and Rwanda to develop a fellowship exchange program to supplement the training of African oncologists practicing in their home countries...
December 2019: Oncologist
https://read.qxmd.com/read/30712734/expressive-writing-to-improve-resilience-to-trauma-a-clinical-feasibility-trial
#9
JOURNAL ARTICLE
Oliver Glass, Mark Dreusicke, John Evans, Elizabeth Bechard, Ruth Q Wolever
BACKGROUND AND PURPOSE: Trauma is highly prevalent, with estimates that up to 90% of the U.S. population have been exposed to a traumatic event. The adverse health consequences of trauma exposure are diverse and often long-lasting. While expressive writing has been shown to improve emotional and physical health in numerous populations, the feasibility and potential effectiveness of a novel expressive writing program provided in a clinical setting to improve resilience is unknown. Our objective was to determine the feasibility and potential effectiveness of a 6-week expressive writing course provided in a clinical setting to improve resilience in individuals with a history of trauma...
February 2019: Complementary Therapies in Clinical Practice
https://read.qxmd.com/read/28334777/clinicians-interpretations-of-point-of-care-urine-culture-versus-laboratory-culture-results-analysis-from-the-four-country-poetic-trial-of-diagnosis-of-uncomplicated-urinary-tract-infection-in-primary-care
#10
RANDOMIZED CONTROLLED TRIAL
Saskia Hullegie, Mandy Wootton, Theo J M Verheij, Emma Thomas-Jones, Janine Bates, Kerenza Hood, Micaela Gal, Nick A Francis, Paul Little, Michael Moore, Carl Llor, Timothy Pickles, David Gillespie, Nigel Kirby, Curt Brugman, Christopher C Butler
Background: Urine culture at the point of care minimises delay between obtaining the sample and agar inoculation in a microbiology laboratory, and quantification and sensitivity results can be available more rapidly in primary care. Objective: To identify the degree to which clinicians' interpretations of a point-of-care-test (POCT) urine culture (Flexicult™ SSI-Urinary Kit) agrees with laboratory culture in women presenting to primary care with symptoms of uncomplicated urinary tract infections (UTI)...
August 1, 2017: Family Practice
https://read.qxmd.com/read/27827358/impact-of-mutational-profiles-on-response-of-primary-oestrogen-receptor-positive-breast-cancers-to-oestrogen-deprivation
#11
RANDOMIZED CONTROLLED TRIAL
Pascal Gellert, Corrinne V Segal, Qiong Gao, Elena López-Knowles, Lesley-Ann Martin, Andrew Dodson, Tiandao Li, Christopher A Miller, Charles Lu, Elaine R Mardis, Alexa Gillman, James Morden, Manuela Graf, Kally Sidhu, Abigail Evans, Michael Shere, Christopher Holcombe, Stuart A McIntosh, Nigel Bundred, Anthony Skene, William Maxwell, John Robertson, Judith M Bliss, Ian Smith, Mitch Dowsett
Pre-surgical studies allow study of the relationship between mutations and response of oestrogen receptor-positive (ER+) breast cancer to aromatase inhibitors (AIs) but have been limited to small biopsies. Here in phase I of this study, we perform exome sequencing on baseline, surgical core-cuts and blood from 60 patients (40 AI treated, 20 controls). In poor responders (based on Ki67 change), we find significantly more somatic mutations than good responders. Subclones exclusive to baseline or surgical cores occur in ∼30% of tumours...
November 9, 2016: Nature Communications
https://read.qxmd.com/read/27036195/heterogeneity-in-global-gene-expression-profiles-between-biopsy-specimens-taken-peri-surgically-from-primary-er-positive-breast-carcinomas
#12
JOURNAL ARTICLE
Elena López-Knowles, Qiong Gao, Maggie Chon U Cheang, James Morden, Joel Parker, Lesley-Ann Martin, Isabel Pinhel, Fiona McNeill, Margaret Hills, Simone Detre, Maria Afentakis, Lila Zabaglo, Andrew Dodson, Anthony Skene, Chris Holcombe, John Robertson, Ian Smith, Judith M Bliss, Mitch Dowsett
BACKGROUND: Gene expression is widely used for the characterisation of breast cancers. Variability due to tissue heterogeneity or measurement error or systematic change due to peri-surgical procedures can affect measurements but is poorly documented. We studied the variability of global gene expression between core-cuts of primary ER+ breast cancers and the impact of delays to tissue stabilisation due to sample X-ray and of diagnostic core cutting. METHODS: Twenty-six paired core-cuts were taken immediately after tumour excision and up to 90 minutes delay due to sample X-ray; 57 paired core-cuts were taken at diagnosis and 2 weeks later at surgical excision...
April 1, 2016: Breast Cancer Research: BCR
https://read.qxmd.com/read/26063881/early-surrogate-markers-of-treatment-activity-where-are-we-now
#13
JOURNAL ARTICLE
Marie Klintman, Mitchell Dowsett
The assessment of new therapies in the adjuvant setting in early breast cancer requires large numbers of patients and many years of follow-up for results to be presented. Therefore, the neoadjuvant study setting, which allows for early prediction of treatment response in smaller patient sets, has become increasingly popular. Ki67 is the most commonly used and extensively studied intermediate biomarker of treatment activity and residual risk in neoadjuvant trials on endocrine therapy, new biological therapies, and chemotherapy...
May 2015: Journal of the National Cancer Institute. Monographs
https://read.qxmd.com/read/25425162/point-of-care-testing-for-urinary-tract-infection-in-primary-care-poetic-protocol-for-a-randomised-controlled-trial-of-the-clinical-and-cost-effectiveness-of-flexicult%C3%A2-informed-management-of-uncomplicated-uti-in-primary-care
#14
RANDOMIZED CONTROLLED TRIAL
Janine Bates, Emma Thomas-Jones, Timothy Pickles, Nigel Kirby, Micaela Gal, Emily Bongard, Kerenza Hood, Nicolas Francis, Paul Little, Michael Moore, Kate Rumsby, Carlos Llor, Curt Burgman, Theo Verheij, David Cohen, Mandy Wootton, Robin Howe, Christopher C Butler
BACKGROUND: Urinary tract infections (UTI) are the most frequent bacterial infection affecting women and account for about 15% of antibiotics prescribed in primary care. However, some women with a UTI are not prescribed antibiotics or are prescribed the wrong antibiotics, while many women who do not have a microbiologically confirmed UTI are prescribed antibiotics. Inappropriate antibiotic prescribing unnecessarily increases the risk of side effects and the development of antibiotic resistance, and wastes resources...
2014: BMC Family Practice
https://read.qxmd.com/read/22043057/endocrine-therapy-new-biologicals-and-new-study-designs-for-presurgical-studies-in-breast-cancer
#15
JOURNAL ARTICLE
Mitch Dowsett, Ian Smith, John Robertson, Laura Robison, Isabel Pinhel, Lindsay Johnson, Janine Salter, Anita Dunbier, Helen Anderson, Zara Ghazoui, Tony Skene, Abigail Evans, Roger A'Hern, Amanda Iskender, Maggie Wilcox, Judith Bliss
The preoperative setting is increasingly popular for the clinical investigation of hormonal agents and new biological drugs. The effectiveness of endocrine agents is well established for estrogen receptor-positive disease, and the emphasis in preoperative studies is on their combination with agents targeted at resistance mechanisms over 3 or more months. New agents are also being assessed for early evidence of clinical efficacy in shorter-term window-of-opportunity studies. The establishment of Ki67 as an intermediate marker of treatment benefit and of long-term outcome, with endocrine drugs, provides the opportunity for new trial designs with Ki67 as the primary endpoint...
2011: Journal of the National Cancer Institute. Monographs
https://read.qxmd.com/read/21949608/systematic-in-vitro-evaluation-of-the-nci-nih-developmental-therapeutics-program-approved-oncology-drug-set-for-the-identification-of-a-candidate-drug-repertoire-for-mll-rearranged-leukemia
#16
JOURNAL ARTICLE
Kimberley A Hoeksema, Aarthi Jayanthan, Todd Cooper, Lia Gore, Tanya Trippett, Jessica Boklan, Robert J Arceci, Aru Narendran
Despite significant progress made in the overall cure rate, the prognosis for relapsed and refractory malignancies in children remains extremely poor. Hence, there is an urgent need for studies that enable the timely selection of appropriate agents for Phase I clinical studies. The Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) is systematically evaluating libraries of known and novel compounds for activity against subsets of high-risk pediatric malignancies with defined molecular aberrations for future clinical development...
2011: OncoTargets and Therapy
https://read.qxmd.com/read/17971465/ordering-suicide-media-reporting-of-family-assisted-suicide-in-britain
#17
JOURNAL ARTICLE
Albert Banerjee, Daphna Birenbaum-Carmeli
OBJECTIVE: To explore the relationship between the presentation of suffering and support for euthanasia in the British news media. METHOD: Data was retrieved by searching the British newspaper database LexisNexis from 1996 to 2000. Twenty-nine articles covering three cases of family assisted suicide (FAS) were found. Presentations of suffering were analysed employing Heidegger's distinction between technological ordering and poetic revealing. FINDINGS: With few exceptions, the press constructed the complex terrain of FAS as an orderly or orderable performance...
November 2007: Journal of Medical Ethics
https://read.qxmd.com/read/17153013/viral-and-bacterial-rhinitis
#18
REVIEW
William J Doyle, Deborah A Gentile, David P Skoner
In contradistinction to the poetically inspired disjunction between the name and quality of a rose recited by Juliet in the famous quote from Shakespeare's play, disease labels used in the medical sciences need to have exact meaning to ensure that they communicate an accurate diagnosis and a valid treatment approach. Above, we presented a consistent nosology for rhinitis consequent to infection. There, we argued that the term "rhinitis" should be used to describe the condition of nasal mucosal pathology and that the rSSC be used to describe the appreciated expression of that pathology...
2007: Clinical Allergy and Immunology
https://read.qxmd.com/read/9378942/the-homo-sexual-temptation-in-milton-s-paradise-regained
#19
JOURNAL ARTICLE
C J Summers
While the sexual temptation of Paradise Regained is tactful, it is also characteristically Miltonic in its daring. Despite its decorous presentation, the temptation is exceedingly bold in that it is not merely a heterosexual temptation but a homosexual one as well. Acknowledgement of the homosexual lure in the brief epic is essential to understanding the dynamics of the celebrated banquet scene and to appreciating the comprehensiveness of Milton's trial of the Son's humanity. Such a recognition also helps place in perspective the alleged misogyny of Paradise Regained, even as it also reveals the complexity of Milton's poetic technique, particularly his ability to work by indirection and implication and to exploit classical and biblical sources...
1997: Journal of Homosexuality
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.